Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status
Vaccines · 13.02.2023 · 11 (2) · 432
DOI: 10.3390/vaccines11020432 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 13.02.2023. Verfasst von Vivek P Chavda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the 21st century, claiming millions of lives and putting a huge burden on the global economy. The potential developments in vaccine technologies following the determination of the genetic sequence of SARS-CoV-2 and the increasing global efforts to bring potential vaccines and therapeutics into the market for emergency use have provided a small bright spot to this tragic event. Several intriguing vaccine candidates have been developed using recombinant technology, genetic engineering, and other vaccine development technologies. In the last decade, a vast amount of the vaccine development process has diversified towards the usage of viral vector-based vaccines. The immune response elicited by such vaccines is comparatively higher than other approved vaccine candidates that require a booster dose to provide sufficient immune protection. The non-replicating adenoviral vectors are promising vaccine carriers for infectious diseases due to better yield, cGMP-friendly manufacturing processes, safety, better efficacy, manageable shipping, and storage procedures. As of April 2022, the WHO has approved a total of 10 vaccines around the world for COVID-19 (33 vaccines approved by at least one country), among which three candidates are adenoviral vector-based vaccines. This review sheds light on the developmental summary of all the adenoviral vector-based vaccines that are under emergency use authorization (EUA) or in the different stages of development for COVID-19 management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India.
- Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh 786004, Assam, India.
- Drug Product Development Laboratory, Biopharma Division, Intas Pharmaceutical Ltd., Moraiya, Ahmedabad 382213, Gujarat, India.
- Pharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India.
- Cell and Gene Therapy Drug Product Development Laboratory, Biopharma Division, Intas Pharmaceutical Ltd., Moraiya, Ahmedabad 382213, Gujarat, India.
- NanoBioTech Laboratory, Health Systems Engineering, Department of Environmental Engineering, Florida Polytechnic University, Lakeland, FL 33805-8531, USA.
ORCID-Profile: Vivek P Chavda, Anup Kumar, Ajeet Kaushik
Zitieren
APA
Chavda, V. P., Bezbaruah, R., Valu, D., Patel, B., Kumar, A., Prasad, S., Kakoti, B. B., Kaushik, A., & Jesawadawala, M. (2023). Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines, 11(2), 432. https://doi.org/10.3390/vaccines11020432
Vancouver
Chavda VP, Bezbaruah R, Valu D, Patel B, Kumar A, Prasad S, et al. Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines. 2023;11(2):432. doi:10.3390/vaccines11020432
BibTeX
@article{Chavda2023,
author = {Chavda, Vivek P and Bezbaruah, Rajashri and Valu, Disha and Patel, Bindra and Kumar, Anup and Prasad, Sanjay and Kakoti, Bibhuti Bhusan and Kaushik, Ajeet and Jesawadawala, Mariya},
title = {Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status},
journal = {Vaccines},
year = {2023},
volume = {11},
number = {2},
pages = {432},
doi = {10.3390/vaccines11020432}
}
EUVIMED